274 related articles for article (PubMed ID: 26359563)
1. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
Makis W; McCann K; Bryanton M; McEwan AJ
Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563
[TBL] [Abstract][Full Text] [Related]
2. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382
[TBL] [Abstract][Full Text] [Related]
3. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
Makis W; McCann K; Buteau FA; McEwan AJ
Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
[TBL] [Abstract][Full Text] [Related]
4. Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies.
Makis W; McCann K; Buteau FA; McEwan AJ
Clin Nucl Med; 2015 Feb; 40(2):162-5. PubMed ID: 25243941
[TBL] [Abstract][Full Text] [Related]
5. Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2015 Nov; 40(11):877-9. PubMed ID: 26204206
[TBL] [Abstract][Full Text] [Related]
6. Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 May; 40(5):e278-81. PubMed ID: 25783505
[TBL] [Abstract][Full Text] [Related]
7. Prolonged response to
Cottereau AS; Bricaire L; Arrondeau J; Dechmi A; Montravers F; Coriat R; Clerc J; Groussin L; Tenenbaum F
Invest New Drugs; 2020 Aug; 38(4):1196-1199. PubMed ID: 31650444
[TBL] [Abstract][Full Text] [Related]
8. Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with
Parghane RV; Basu S
J Nucl Cardiol; 2020 Feb; 27(1):340-341. PubMed ID: 30151794
[No Abstract] [Full Text] [Related]
9. Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2015 Nov; 40(11):880-4. PubMed ID: 26359564
[TBL] [Abstract][Full Text] [Related]
10. Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy.
Makis W; McCann K; Buteau FA; McEwan AJ
Clin Nucl Med; 2015 Jul; 40(7):564-6. PubMed ID: 25546192
[TBL] [Abstract][Full Text] [Related]
11. Hepatopulmonary Shunt Reduction With 177Lu-DOTATATE Therapy.
Acar E; Çapa Kaya G; Durak H
Clin Nucl Med; 2016 Nov; 41(11):866-871. PubMed ID: 27607172
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
[No Abstract] [Full Text] [Related]
13. The efficacy of
Zhang J; Song Q; Cai L; Xie Y; Chen Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
[TBL] [Abstract][Full Text] [Related]
14. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
15. Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery.
Schmidt MC; Uhrhan K; Fischer T; Schmitz S; Markiefka B; Drzezga A; Stippel D
Clin Nucl Med; 2015 Aug; 40(8):667-9. PubMed ID: 26053706
[TBL] [Abstract][Full Text] [Related]
16. Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy.
Makis W; McCann K; Riauka TA; McEwan AJ
Clin Nucl Med; 2016 Jan; 41(1):50-2. PubMed ID: 26359569
[TBL] [Abstract][Full Text] [Related]
17. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment.
Parghane RV; Mitra A; Upadhye T; Rakshit S; Banerjee S; Basu S
Clin Nucl Med; 2020 Sep; 45(9):714-715. PubMed ID: 32657872
[TBL] [Abstract][Full Text] [Related]
18.
Das S; Al-Toubah T; El-Haddad G; Strosberg J
Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1023-1031. PubMed ID: 31652074
[No Abstract] [Full Text] [Related]
19. Twelve-Year Survival of a Patient With Lymph Node, Pulmonary, Bone, Cardiac and Intraspinal Metastases of a Rectal Neuroendocrine Neoplasm Treated With Peptide Receptor Radionuclide Therapy-The Value of Salvage Peptide Receptor Radionuclide Therapy.
Zhang J; Kulkarni HR; Singh A; Baum RP
Clin Nucl Med; 2020 Apr; 45(4):e198-e200. PubMed ID: 31876836
[TBL] [Abstract][Full Text] [Related]
20. Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event.
Karfis I; Marin G; Machiels G; Hendlisz A; Flamen P
Clin Nucl Med; 2018 Jul; 43(7):e232-e233. PubMed ID: 29762236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
